Abstracts tagged "risk and treatment guidlelines"

Abstract Number: 3117 • 2015 ACR/ARHP Annual Meeting
Under-Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease – an International Multicentre Study
Lihi Eder¹, Vinod Chandran¹, Cheryl Rosen², Jan Dutz³, James T. Elder⁴, Proton Rahman⁵, Christopher T. Ritchlin⁶, Francisco A. Tausk⁷, Sherry Rohekar⁸, Richard Hayday⁹, Snezana Barac¹⁰, Devy Zisman¹¹, Joy Feld¹² and Dafna D. Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴University of Michigan Medical School, Ann Arbor, MI, ⁵Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁷University of Rochester Medical Center, Rochester, NY, ⁸Western University, London, ON, Canada, ⁹University of Manitoba, Winnipeg, MB, Canada, ¹⁰Winnipeg Clinic, Winnipeg, MB, Canada, ¹¹Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ¹²Carmel Medical Center, Haifa, Israel
Background/Purpose: Cardiovascular risk in patients with psoriatic disease is partly attributed to the high prevalence of traditional cardiovascular risk factors in these patients. This study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].